ArticleMolecular cell2021
Interaction of tau with HNRNPA2B1 and N
Open access · greenAbstract readVideo-Audio Media
In one paragraph
Article in Molecular cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 182 citations in OpenAlex.
- Mechanistic studies on HNRNPA2B1 suggest binding but not selective recognition of mRNA biology · 2026Article
- circNLK restrains glioblastoma malignancy by binding to hnRNP L and destabilizing RGS16.Non-coding RNA research · 2026Article
- Elevation of the mechanically-sensitive e protein emerin links nuclear mechanotransduction to tau-induced cytoskeletal remodeling in neurons.Nucleus (Austin, Tex.) · 2026Article
- Nuclear membrane disruption in neurodegenerative diseases: Emerging perspectives.Neural regeneration research · 2026Article
- Review
- Proteomic screening identifies HNRNPA2B1 as an epigenetic repressor of Epstein-Barr virus reactivation.Journal of virology · 2026Article
- HnRNPA2B1 tunes antimycobacterial immune responses in macrophages through alternative splicing ofInfection and immunity · 2026Article
- Nuclear dysfunction in aging and neurodegeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Riboregulation: a non-canonical tau function.Molecular neurodegeneration · 2026Review
- FKBP51 inhibition by SAFit2 modulates tau pathology and cognitive deficits in PS19 mice.Alzheimer's research & therapy · 2026Article
- Neuromodulatory role and therapeutic potential of N 6 -methyladenosine RNA methylation in neurodegenerative diseases.Neural regeneration research · 2026Article
- ALKBH3 m1A Demethylase Deficiency Reduces Alzheimer's Amyloid-β Pathology.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- FERPIR promotes cardiomyocyte survival and attenuates cardiac remodeling after myocardial infarction.Cell death & disease · 2026Article
- MXene-Protein Corona Interfaces for Molecular Profiling of Alzheimer's Disease.bioRxiv : the preprint server for biology · 2026Article
- Review
- Roles of RNA-Binding Nuclear Proteins in Alzheimer's Disease Pathophysiology.ACS pharmacology & translational science · 2026Review
- RNArchitects: how hnRNPs shape neuronal landscapes.Brain : a journal of neurology · 2026Review
- Tau oligomerization induces nuclear lamina invagination and chromatin remodeling in Alzheimer's disease.Acta neuropathologica · 2026Article
- m6A RNA methylation in neural plasticity, brain aging, and neurodegenerative vulnerability.Molecular brain · 2026Review
- IR-AMES uncovers structure and composition of Alzheimer's tau oligomers.bioRxiv : the preprint server for biology · 2026Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 6 institutions in 1 country.
Lulu JiangDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Weiwei LinCenter for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
Cheng ZhangDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Peter E A AshDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Mamta VermaDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Julian KwanCenter for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
Emily van VlietDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Zhuo YangDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Anna Lourdes CruzDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Samantha BoudeauDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Brandon F MaziukDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Shuwen LeiDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Jaehyup SongDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA.
Victor E AlvarezDepartment of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
Stacy HovdeDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.
Jose F AbisambraDepartment of Neuroscience, University of Florida, Gainesville, FL 32611, USA.
Min-Hao KuoDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA.
Nicholas KanaanDepartment of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, MI 49503, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
John F CraryDepartment of Pathology, Mount Sinai Medical Center, New York, NY 10029, USA.
Jian ZhaoDepartment of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.
Ji-Xin ChengDepartment of Electrical and Computer Engineering, Boston University, Boston, MA 02459, USA.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL 32224, USA.
Hu LiDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Andrew EmiliCenter for Network Systems Biology, Boston University School of Medicine, Boston, MA 02118, USA.
Benjamin WolozinDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA 02118, USA; Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; Center for Neurophotonics, Boston University, Boston, MA 02215, USA; Center for Systems Neuroscience, Boston University, Boston, MA 02215, USA. Electronic address: bwolozin@bu.edu.
Boston University · USMichigan State University · USMayo Clinic · USMayo Clinic in Florida · USMount Sinai Medical Center · USUniversity of Florida · US
Funding
Neuropathology CoreP30AG013846 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI KOWALL, NEIL W. · 1996 to 2020
$29.1MThe Goizueta Alzheimer's Disease Research CenterP30AG066511 · NIA · EMORY UNIVERSITY · PI Amy D Rodriguez · 2020 to 2026
$29.0MCapturing the molecular complexity of Alzheimer's disease through the lens of RNA binding proteinsRF1AG056318 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI LI, HU, WOLOZIN, BENJAMIN L · 2018 to 2020
$4.4MSystems-level functional proteomics analysis assemblies in Alzheimer's disease and mouse models of tauopathyRF1AG061706 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI EMILI, ANDREW, WOLOZIN, BENJAMIN L · 2019 to 2019
$3.9MCircular RNAs and their interactions with RNA-binding proteins to modulate AD-related neuropathologyU01AG072577 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WOLOZIN, BENJAMIN L, ZHANG, XIAOLING · 2021 to 2025
$3.8MGenetic Modifiers of Protein Interaction Networks in TauopathyR01AG064932 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI EMILI, ANDREW, WOLOZIN, BENJAMIN L · 2019 to 2023
$3.2MRNA binding proteins as novel targets in Alzheimer's diseaseR01AG050471 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI WOLOZIN, BENJAMIN L · 2015 to 2019
$2.9MThe role of acetylation in regulating pathophysiology of tauR01NS089544 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD, WOLOZIN, BENJAMIN L · 2014 to 2018
$1.9MQUANTSTUDIO 12K FLEX OPEN ARRAY REAL-TIME PCR SYSTEMS10OD023663 · OD · BOSTON MEDICAL CENTER · PI DENG, LINGYI L · 2017 to 2017
$186kNIA NIH HHS P30 AG013846NIA NIH HHS P30 AG066511NIA NIH HHS R01 AG050471NIA NIH HHS R01 AG064932NIA NIH HHS RF1 AG056318NIA NIH HHS RF1 AG061706NIA NIH HHS U01 AG072577NIH HHS S10 OD023663NINDS NIH HHS R01 NS089544
Abstract
The microtubule-associated protein tau oligomerizes, but the actions of oligomeric tau (oTau) are unknown. We have used Cry2-based optogenetics to induce tau oligomers (oTau-c). Optical induction of oTau-c elicits tau phosphorylation, aggregation, and a translational stress response that includes stress granules and reduced protein synthesis. Proteomic analysis identifies HNRNPA2B1 as a principle target of oTau-c. The association of HNRNPA2B1 with endogenous oTau was verified in neurons, animal models, and human Alzheimer brain tissues. Mechanistic studies demonstrate that HNRNPA2B1 functions as a linker, connecting oTau with N
Indexed as
RNA Processing, Post-TranscriptionalAdenosineAgedAged, 80 and overAlzheimer DiseaseAnimalsCase-Control StudiesCerebral CortexDisease Models, AnimalDisease ProgressionFemaleHEK293 CellsHeterogeneous-Nuclear Ribonucleoprotein Group A-BHumansMaleMethylationAdenosineHeterogeneous-Nuclear Ribonucleoprotein Group A-BhnRNP A2MAPT protein, humanN-methyladenosineProtein AggregatesRNAtau ProteinsAlzheimer's diseasefibrilslaminMETTL3neurodegenerationnuclear envelopeRNA methylationRNA translationstress granulestau oligomerization
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.